MEDICAID POLICY INFORMATION SHEET

Policy Analyst: Vicki Goethals

Phone Number:

Initial 🗌	Public Comment 🛛	Final 🗌	

Brief description of policy:

This bulletin describes the termination of several COVID-19 pharmacy policies, including coverage for FDA EUA monoclonal antibody injections by pharmacy providers, stand-alone vaccine counseling services billed as Medication Therapy Management (MTM) claims, and pharmacist prescriptive authority to order oral antivirals for the treatment of COVID-19 under the PREP Act. Termination of coverage and reimbursement outlined with the policy is effective for dates of service on and after October 1, 2024. These terminations were previously announced in bulletin MMP 23-27.

Reason for policy (problem being addressed):

Mandatory Medicaid coverage of certain COVID-19 treatments and services specified under the American Rescue Plan Act of 2021 (ARP) ends September 30, 2024. Due to the reduction in public emergency conditions, MDHHS has chosen not to extend these special coverages.

Budget implication:

budget neutral
 will cost MDHHS \$, and (select one) budgeted in current appropriation
 will save MDHHS \$ Unknown

Is this policy change mandated per federal requirements?

Yes, these authorities granted per ARP end after September 30, 2024.

Does policy have operational implications on other parts of MDHHS?

No

Does policy have operational implications on other departments?

No

Summary of input:

- controversial (Explain)
- \boxtimes acceptable to most/all groups
 - limited public interest/comment

Supporting Documentation:

State Plan Amendment Required: Yes 🛛 No			Public Notice Required:	Yes	🛛 No	
If Yes, please provide status:						
Approved	Pending	Dei Dei	nied	If yes,		
Date:	Approval	Date:		Submission Date:		

H		I						
DRAFT FOR PUBLIC COMMENT Michigan Department of Health and Human Services								
		Project Number: 2424-Pharmacy Date: July 11, 2024						
Comments Due: Proposed Effective Date: Direct Comments To: Address: E-Mail Address: Phone:	Octo Vicki	ust 15, 2024 bber 1, 2024						
	Policy Subject: End of the Federal Public Health Emergency and Final Unwinding of Pharmacy COVID-19 Response Policies							
Affected Programs: Medicaid, Healthy Michigan Plan, MIChild, Maternity Outpatient Medical Services (MOMS), Children's Special Health Care Services (CSHCS)								
Distribution: All Providers								
Summary: This policy concludes three temporary COVID-19 Medicaid Pharmacy provisions due to the COVID-19 public health emergency (PHE), declared under Section 319 of the Public Health Service Act: bulletin <u>HASA 22-02</u> , <u>MMP 22-29</u> , and letter <u>L 22-04</u> .								
Purpose: Budget Saving								
Cost Implications: Budget	Savin	ıg						
Potential Hearings & Appeal Issues: Aware of None								
State Plan Amendment Required: Yes No Public Notice Required: Yes No If yes, date submitted: Submitted date:								
Tribal Notification: Yes 🗌 No 🖾 - Date:								
THIS SECTION COMPLETED BY RECEIVER								
Approved			No Comments	Delaur				
Disapproved		See Comments BelowSee Comments in Text						
Signature:			Phone Num	ber				
Signature Printed:								
Bureau/Administration (please print)			Date	Date				
Comment001				Revised 6/16				

Proposed Policy Draft

Michigan Department of Health and Human Services Behavioral & Physical Health and Aging Services Administration

 Distribution:
 All Providers

 Issued:
 August 30, 2024 (Proposed)

 Subject:
 End of the Federal Public Health Emergency (PHE) and Final Unwinding of Pharmacy COVID-19 Response Policies

 Effective:
 October 1, 2024 (Proposed)

Programs Affected: Medicaid, Healthy Michigan Plan, MIChild, Maternity Outpatient Medical Services (MOMS), Children's Special Health Care Services (CSHCS)

Due to the COVID-19 public health emergency (PHE), the Michigan Department of Health and Human Services (MDHHS) issued several COVID-19 pharmacy policies during the declared period of the PHE. This bulletin notifies providers of the intent to discontinue the remaining COVID-19 pharmacy coverage and reimbursement policies.

This policy concludes three temporary COVID-19 Medicaid Pharmacy provisions due to the COVID-19 PHE, declared under Section 319 of the Public Health Service Act: Bulletin <u>HASA 22-02</u>, <u>MMP 22-29</u>, and letter <u>L 22-04</u>. These provisions were extended in Sections 9811 and 9821 of the American Rescue Plan Act of 2021 (ARP) for coverage of COVID-19 treatment services, and declared in bulletin <u>MMP 23-27</u>. As defined by the ARP, the policy provisions below were extended effective for dates of service on and after March 11, 2021, through the last day of the first calendar quarter that begins one year after the last day of the PHE period described in Section 1135(g)(1)(B) of the Social Security Act, which is September 30, 2024.

MDHHS is concluding the process of unwinding these provisions as the authorities for these policies expire.

- <u>HASA 22-02</u> Authorization of U.S. Food & Drug Administration (FDA) Emergency Use Authorization (EUA) pharmacist prescriptive authority of oral antivirals for the treatment of COVID-19;
- <u>MMP 22-29</u> Coverage of FDA EUA COVID-19 monoclonal antibody injections by pharmacy providers; and
- <u>L 22-04</u> Stand-alone vaccine counseling services billed as a Medication Therapy Management service.

Following the expiration of the ARP defined effective period dates, Medicaid pharmacy requirements will revert to existing Medicaid policies and State Plan authorities.